Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005664809
Wed, 04.05.2022
Evotec SE
Hamburg, Germany, 04 May 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first quarter of 2022 on Wednesday, 11 May 2022.
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference c [ … ]
Tue, 12.04.2022
Evotec SE
STRONG FINANCIAL RESULTS: 23% INCREASE IN GROUP REVENUES SIGNIFICANTLY EXCEEDING GUIDANCE
DATA-DRIVEN PLATFORMS AND TECHNOLOGIES INCREASE PROBABILITIES OF SUCCESS IN ALL MODALITIES
SUBSTANTIALLY STRENGTHENED BALANCE SHEET PROVIDING VERY GOOD FOUNDATION AND LEVERAGE FOR SUSTAINABLE, LONG-TERM GROWTH
POSITIVE OUTLOOK INTO FISCAL YEAR 2022
Hamburg, [ … ]
Fri, 08.04.2022
Evotec SE
THE PROGRAMME DESIGNATION IS BASED ON AN ANTISENSE-BASED APPROACH WHICH TRIGGERS A US$ 16 M PAYMENT TO EVOTEC BY BRISTOL MYERS SQUIBB
EVOTEC SOURCES LNAPLUS(TM) ANTISENSE TECHNOLOGY THROUGH A STRATEGIC PARTNERSHIP WITH SECARNA PHARMACEUTICALS
Hamburg, Germany, 08 April 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809 [ … ]
Tue, 05.04.2022
Evotec SE
Hamburg, Germany, 05 April 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2021 on Tuesday, 12 April 2022.
The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in [ … ]
Mon, 21.03.2022
Evotec SE
FIRST DOSING OF A STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 3 M TO EVOTEC
PHASE II CLINICAL TRIAL INITIATED BY EVOTEC'S PARTNER BAYER TO EVALUATE BAY 2395840 AS A POTENTIAL TREATMENT FOR DIABETIC NEUROPATHIC PAIN
Hamburg, Germany, 21 March 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announc [ … ]
Wed, 02.03.2022
Evotec SE
LAUNCH OF E.MPD, THE LEADING GLOBAL MOLECULAR PATIENT DATABASE
ROLL-OUT AND ACCELERATION OF AI/ML PRECISION TECHNOLOGIES TO INCREASE PROBABILITY OF SUCCESS ("POS") IN RESEARCH, DEVELOPMENT, AND MANUFACTURING
EXPANSION OF MANAGEMENT BOARD WITH NEW CHIEF BUSINESS OFFICER (CBO) DR MATTHIAS EVERS AS EXPERT IN AI/ML DRIVEN PROCESSES
Hamburg, Germany, [ … ]
Tue, 01.03.2022
Evotec SE
EVOTEC RECEIVES ACCESS TO AN INTERNATIONAL COHORT OF NEPHROTIC SYNDROME PATIENTS COORDINATED BY THE UNIVERSITY OF BRISTOL
THE COHORT PROVIDES LONGITUDINAL ACCESS NOT ONLY TO CLINICAL DATA BUT IN PARTICULAR ALSO TO BIOSPECIMENS
EVOTEC WILL LEVERAGE ITS MULTI-OMICS ANALYSIS PLATFORM EVOPANOMICS AND THE DATA ANALYTICS PLATFORM EVOPANHUNTER TO IDENTI [ … ]
Tue, 25.01.2022
Evotec SE
PARTNERSHIP LEVERAGES EVOTEC'S HUMAN IPSC-BASED PHENOTYPIC SCREENING AND PANOMICS PLATFORMS
AIM IS TO IDENTIFY AND VALIDATE PROMISING TARGETS AND NEW APPROACHES FOR THERAPEUTIC INTERVENTIONS
Hamburg, Germany, 25 January 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company ha [ … ]
Tue, 18.01.2022
Evotec SE
COLLABORATION LEVERAGES EVOTEC'S BROAD METABOLIC EXPERTISE AND UNIQUE KIDNEY DISEASE PATIENT DATABASE AS WELL AS INTEGRATED DATA-DRIVEN DRUG DISCOVERY AND DEVELOPMENT PLATFORMS
LILLY HAS THE RIGHT TO SELECT UP TO FIVE PROGRAMMES
Hamburg, Germany, 18 January 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NAS [ … ]
Tue, 11.01.2022
Evotec SE
EXPANSION LEVERAGES A PROPRIETARY EVOTEC PLATFORM IN THE FIELD OF TARGETED PROTEIN DEGRADATION TO TACKLE SELECTED TARGETS WITH RELEVANCE FOR A RANGE OF NEURODEGENERATIVE CONDITIONS
EVOTEC RECEIVES PAYMENTS OF IN TOTAL US$ 15 M FROM BRISTOL MYERS SQUIBB
Hamburg, Germany, 11 January 2022:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISI [ … ]